Peter Roumeliotis, MD
Internal Medicine · Morris, ILNPI 1942280326
Payments from drug & device makers
Across 82 payments — averaging $34.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$350
- Boehringer Ingelheim$315
- Sunovion Pharmaceuticals Inc.$283
- Amgen$258
- Novartis$240
- Novo Nordisk$193
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,819100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $350 |
| Boehringer Ingelheim | 12 | $315 |
| Sunovion Pharmaceuticals Inc. | 9 | $283 |
| Amgen | 5 | $258 |
| Novartis | 15 | $240 |
| Novo Nordisk | 6 | $193 |
| Amarin Pharma, Inc. | 3 | $156 |
| Abbott | 1 | $140 |
| Si-bone, Inc. | 1 | $140 |
| AstraZeneca | 2 | $139 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Bayer | 1 | $124 |
| Edwards Lifesciences | 1 | $79 |
| Philips North America LLC | 4 | $54 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Exact Sciences | 1 | $25 |
| Pfizer | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$229
- FREESTYLE LIBRE 3$140
- LONHALA MAGNAIR$125
- BREZTRI$125
- Saxenda$125
- ZENPEP$125
- Kerendia$124
- Vascepa$123
- AIMOVIG$122
- JARDIANCE$121
How this compares
$2,819 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 443 | $203,487 |
| OfevNintedanib Esylate | 12 | $156,004 |
| JardianceEmpagliflozin | 53 | $67,657 |
| FarxigaDapagliflozin Propanediol | 76 | $60,459 |
| OzempicSemaglutide | 55 | $58,960 |
| XareltoRivaroxaban | 65 | $41,710 |
| XifaxanRifaximin | 12 | $35,842 |
| JanuviaSitagliptin Phosphate | 38 | $29,458 |
| MyrbetriqMirabegron | 116 | $23,671 |
| MounjaroTirzepatide | 23 | $22,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,074 |
| RybelsusSemaglutide | 13 | $16,540 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $16,199 |
| NamzaricMemantine Hcl/Donepezil Hcl | 64 | $14,696 |
| TrulicityDulaglutide | 13 | $13,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance | $315 | $223,66165 claims |
| PfizerEliquis | $24 | $203,487443 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $139 | $76,65890 claims |
| Novo NordiskOzempic, Rybelsus | $193 | $75,50068 claims |
| Johnson & JohnsonXarelto | $350 | $41,71065 claims |
| Lilly USA, LLCMounjaro, Trulicity | $11 | $36,26536 claims |
| NovartisEntresto | $240 | $6,43823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Morris
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.